Background 1 in 3 people carry CYP2C19 mutations that can impair drug metabolism.1 15% of all prescribed drugs are metabolized by CYP2C19 enzymes2, including Plavix® (clopidogrel), Inderal® (propranolol), Celexa® (citalopram), Prevacid® (lansoprazole), Losec® (omeprazole), Elavil® (amitriptyline), Valium® (diazepam), Dilantin® (phenytoin), and more. Example: Clopidogrel resistance & cardiac stents 42% higher risk of death, stroke, and heart attack in CYP2C19 carriers.3 Plavix® (clopidogrel) FDA black box warning for CYP2C19 poor metabolizers. Indications for Use The Spartan RX CYP2C19 System is indicated for use as an aid to clinicians in determining therapeutic strategies for therapeutics that are metabolized by the Cytochrome P450 2C19 gene product, and that are specifically affected by the *2, *3, and *17 alleles. The Spartan RX CYP2C19 Assay will be run on the Spartan RX Platform. The Spartan RX CYP2C19 Assay is not indicated to be used to predict drug response or non-response. Size and Weight Spartan RX Analyzer Height: 4.7 inches (12 cm) Width: 6.7 inches (17 cm) Dept: 14.2 inches (36 cm) Weight: 9.3 pounds (4.2 kg) Electrical Requirements Electrical Compatibility: 100 to 240 VA, 50 to 60 Hz Maximum Electrical Power: 150W to 500W Analyzer: 100W peak Netbook: 40W peak Printer: 9W peak Operating Voltage: 12.0V +/-5% Operating Current: 6.5A Maximum Environmental Requirements Designed for indoor use only Operating Ambient Temperature: 18° to 25° C (64.4° to 77° F) Operating Relative Humidity: 30% to 70% Non-condensing